The KRISTINE trial showed that, in patients with HER2+ BC, traditional neoadjuvant systemic chemotherapy plus a dual HER2-targeted blockade (docetaxel, carboplatin, trastuzumab, and pertuzumab) produced a significantly higher pCR than T-DM1 plus pertuzumab (55.7% vs. 44.4%; p = 0.016) but was associated with numerically more grade 3/4 and serious adverse events than the T-DM1-containing regimen [93]. Here, ERBB2 is linked to breast cancer.